Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Aug…
Biotechnology
US, Bedford [HQ]
Investor Relations
Filing Reader · Print Documents · Transcripts
Could not find a transcript
Peer Group
Peers Analysis-
Sorry! None of STOK's peers has listed transcripts.
Upcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts